Bio-Rad Q3 Revenue Edges Past Estimates as Clinical Diagnostics Offsets Life Science Weakness
BIO sits 60% above its 52-week low of $236.73.
Summary
Q3 revenue came in at $656.40 million versus $649.95 million consensus — a beat of under 1%, so barely a beat. Adjusted EPS rose to $2.65 from $2.26 a year earlier, a real improvement in core profitability. Growth came from Clinical Diagnostics, specifically quality systems and diabetes products, plus higher Droplet Digital PCR demand; that offset declines in Life Science, where process chromatography and academic research spending stayed weak. The reported $458.6 million net income is almost entirely a non-cash mark-to-market gain on the Sartorius stake, not operations — the 8-K filed this afternoon shows core operations lost $49.7 million after restructuring and a Celsee charge. Guidance is the soft spot: 2026 non-GAAP currency-neutral revenue of down 3% to up 0.5%, with operating margin held at 10% to 12%. Stock sits near its 52-week high at roughly 37x forward earnings, so the bar was high and this is a modest pass, not a blowout.
At the time of this announcement, BIO was trading at $379.29 on NYSE in the Life Sciences sector, with a market capitalization of approximately $10.2B. The 52-week trading range was $236.73 to $396.23. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Reuters.